Your World, Fully Explored.

Published 2 years ago • loading... • Updated 2 years ago

Merck and Eisai say two lung-cancer trials failed to meet their main goals

Summary by Ground News

Two late-stage trials of a treatment for a certain type of non-small lung cancer failed to meet their primary goals. The companies said they would continue to push ahead with their research. Merck's stock is down 3.8% in the year to date, while the S&P 500 SPX has gained 12.8%.

2 Articles

2 Articles

All

Left

Center

2

Right

Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer - Merck & Co (NYSE:MRK)

Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC:

2 years ago·New York, United States

Read Full Article

Merck and Eisai say two lung-cancer trials failed to meet their main goals

Two late-stage trials of a treatment for a certain type of non-small lung cancer failed to meet their primary goals, the companies said Friday.

2 years ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources2

Leaning Left0Leaning Right0Center2Last Updated2 years agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

MarketWatch broke the news in United States 2 years ago on Friday, September 22, 2023.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics